Earnings Call
Aug 11, 2026
Q2 FY2026
EPS Estimate
2.42
EPS Actual
2.63
Post-Earnings Close
$240.26
Earnings Reaction
+1.3%
Cardinal Health's fiscal second quarter delivered broad-based earnings momentum that exceeded expectations across every operating segment, with non-GAAP diluted EPS of $2.63, up 36% year-over-year and well ahead of the $2.42 consensus estimate. Total revenue rose 19% to $66 billion, driven primarily by continued strength in Pharmaceutical and Specialty Solutions, where revenue climbed 19% to $61 billion and segment profit surged 29% to $687 million. The company promptly raised its full-year FY2026 non-GAAP EPS guidance to $10.15, $10.35, representing 23%, 26% year-over-year growth, and lifted its pharma segment profit growth outlook to 20%, 22% from the prior 16%, 19% range. The breadth of the beat, double-digit profit growth in all five operating segments, is the defining feature of this quarter and signals that execution, not just favorable mix, is driving results.
Report generated on Aug 10, 2026
AI-generated earnings analysis. Not investment advice.
Chief Executive Officer
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
The quarter's results reflected a combination of company-specific execution and broader sector dynamics, with management addressing several of the key debates that analysts had flagged heading into the print. Guidance commentary pointed to continued momentum in the core segments, while questions on margins and capital allocation drew more nuanced responses from the leadership team over the course of the call.
Read the full CAH analysis
The complete report, with key themes, analyst Q&A summary, notable quotes, and market context — is free with an account. No password, no card.